Real-Time Diagnostics

Name

Real-Time Diagnostics

Legal name

Real-Time Diagnostics

Website

https://rtdlabs.com

Company type

Private

Founded year

2009

Operating status

Operating

Headcount range

11–50 employees

Ownership category

akta.pro rank

Product category

Anticoagulation Management Services

NAICS

Medical and Diagnostic Laboratories (62151), Home Health Care Services (621610)

SIC

Services-Medical Laboratories (8071), Services-Home Health Care Services (8082)

akta.pro industry

PRIMARYHLACAPAK

Remote Diagnostics & Point-of-Care (Connected Testing, Home Lab Devices)

Healthcare & Life Sciences/Digital Health & Health IT/Healthcare IoT & Remote Patient Monitoring

SECONDARYHLAHACAI

Chronic Disease Remote Monitoring (COPD/CHF/HTN, Weight & Symptom Tracking)

Healthcare & Life Sciences/Medical Devices & Diagnostics/Patient Monitoring, Wearables & Remote Diagnostics

SECONDARYHLALAAAE

At-Home Lab Testing & Diagnostics-Integrated Virtual Care

Healthcare & Life Sciences/Telehealth Platforms/Direct-to-Consumer Virtual Care Platforms

Keywords

• Anticoagulation management services
• PT INR home testing
• Coumadin monitoring programs
• Warfarin dosage management
• Patient self testing services

Headquarters

HQ city

Warren

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Marketing or Sales, Supply Chain

Revenue model

1. Patient Self-Testing Services: RTD provides PT/INR home self-testing services for patients on long-term Coumadin therapy. The company bills insurance (including Medicare and private health plans) for these services. Insurance typically covers up to 52 PT/INR self-tests per year (once per week). Revenue is generated through insurance reimbursements and may include co-pay/coverage from patients.
2. Dosage Management Services: Optional clinical service where RTD's pharmacists and clinical staff provide dosage management for patients, including medication management reviews. This is an enhanced service offering that generates additional revenue beyond basic self-testing.

Pricing tiers

Go-to-market motion1 record

Distribution channels3 records

Marketing channels4 records

Core offering

Real-Time Diagnostics provides a customized PT/INR home self-testing program for patients on long-term Coumadin/Warfarin therapy. The Integrated INR Management Program bundles weekly self-testing supplies, pharmacist-led dosage and medication management, clinical oversight, and multi-channel result reporting (online portal, fax, email, phone) to physicians and health plans. Services are prescribed by healthcare providers and reimbursed through Medicare and major private health plans.

Product overview

Real-Time Diagnostics offers a single integrated healthcare service focused on PT/INR home self-testing for patients on long-term Coumadin/Warfarin therapy. The core offering is the Integrated INR Management Program, which combines patient self-testing services with clinical support including optional Dosage Management Services and Medication Management Review. The company provides comprehensive data reporting tools and 24/7 pharmacist/clinical staff availability. Supporting materials include educational booklets (My Coumadin Therapy and PT/INR Self-Testing Booklet, A Heart-Healthy Approach for Foods Containing Vitamin K), instructional guides (10 Steps To Test, Fingerstick Guide, Pipette Guide), and Zoom Video Training for remote patient education. The program accepts various insurance plans including Medicare, Aetna, BC/BS, Cigna, Humana, and United Healthcare.

Differentiator

Problem solved

Functional benefit

Products and services

• Integrated INR Management Program Comprehensive PT/INR home self-testing program for patients on long-term Coumadin/Warfarin therapy, bundling weekly self-testing, pharmacist-led dosage and medication management, and continuous clinical oversight with multi-channel reporting (online portal, fax, email, phone) to physicians and health plans.
• Patient Self-Testing Services Enables patients to check their PT/INR levels at home or while traveling via a fingerstick blood test, including initial meter training by RTD clinical staff and ongoing phone support; services are reimbursed by Medicare and major private health plans.
• Dosage Management Services Optional clinical service in which RTD pharmacists and clinical staff provide dosage recommendations and ongoing monitoring for Coumadin patients to keep patients within therapeutic INR range.
• Medication Management Review Optional clinical service in which pharmacists review a patient's medications and address triggers that impact Coumadin levels and medication adherence.
• Comprehensive Data and Reporting Provides real-time visibility and immediate notification of INR results and patient data to physicians and health plans through an online portal, fax, phone, and email.

Quantifiable outcome

• 70.1% average time in therapeutic range (TTR) exceeds industry average
• +3 more outcomes

Named customers3 records

Segments2 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration3 records

Feature3 records

Partnerships

Four partnerships are on record, tiered core.

• Advanced Cardiovascular Associates, PLCcoreStrategic or Co-development Partner · 1 January 20125-year partnership (since 2012) for INR Management of long-term Coumadin therapy patients. Advanced Cardiovascular Associates was drawn to RTD's unique clinical program which includes dosage management, medication therapy management, and patient education - differentiating RTD from other PST companies.
• Spectrum Health Medical Group Anticoagulation CliniccoreStrategic or Co-development Partner · 1 January 2010Long-standing partnership since 2010 for patient self-testing services. Spectrum Health Medical Group Anticoagulation Clinic in Michigan utilizes RTD's PST services as an integral part of their service offering for cardiac care.
• Stuart Cardiology GroupcoreStrategic or Co-development PartnerCardiology practice partnership for comprehensive INR management program with dosage management services. The practice chose RTD for their growing patient volume and expanding practice needs.
• Medicare and Private Insurance PlanscoreChannel Partner/ Reseller/ DistributorInsurance coverage accepted including Medicare, Medicare Plus Blue, and private plans such as Aetna, Blue Cross/Blue Shield, Cigna, Humana, United Healthcare, and many others. Insurances typically cover up to 52 PT/INR self-tests per year.

Scale indicators4 records

Recent moves5 records

Expansion highlights3 records

Emerging players

• iRhythm Technologies: iRhythm is a digital cardiac monitoring company (Zio patch) that occupies an adjacent remote-monitoring slot in cardiology, representing where connected chronic-care monitoring is heading and a potential long-term adjacent competitor.
• HemoSonics (formerly ITC): HemoSonics, successor to International Technidyne Corporation which produced the ProTime PT/INR meter, operates in the same point-of-care coagulation diagnostics space and shares RTD's reliance on warfarin monitoring end markets.

Broad incumbents

• Quest Diagnostics: Quest Diagnostics is a national reference laboratory offering INR and coagulation testing services, including self-testing programs that overlap with RTD's value proposition for chronic-care warfarin patients.
• Abbott (formerly Alere): Abbott acquired Alere's INRatio PT/INR self-testing franchise and broader diagnostics portfolio, giving it scale advantages and established payer relationships in the same INR self-testing category where RTD operates.
• Labcorp: Labcorp is a national reference laboratory providing INR testing services and self-testing logistics, competing with RTD at the lab-services layer and through its payer contracts across the same patient population.

Direct peers

• CoaguSense: CoaguSense is a US-based PT/INR meter manufacturer competing directly in the home and point-of-care INR self-testing market served by RTD.
• Roche Diagnostics (CoaguChek): Roche manufactures the dominant CoaguChek PT/INR self-testing meter and operates associated patient self-testing services in the US, directly competing with RTD on both the device and the wraparound clinical service.
• mdINR: mdINR provides a near-identical patient self-testing (PST) program for warfarin patients, including home INR meters, training, and reporting, making it the closest direct competitor to RTD's core service.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• Facebookfacebook.com/profile.php
• LinkedInlinkedin.com/company/real-time-diagnostics-inc.

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Real-Time Diagnostics